Get your one-off screening for hepatitis B from your GP in Germany
Hepatitis B can be treated well at an early stage, hepatitis C can even be cured. In Germany, like in other countries and regions of the world, many people affected are unaware of their infection. Since 1st October 2021, people living in Germany are now entitled to a one-off screening from the age of 35 at no extra cost carried out by their GP. In order to detect and treat infections with hepatitis B and hepatitis C viruses as early as possible, screening for both viruses in the health check-up for people with statutory health insurance as a health insurance benefit as of 1st October. The guidelines of the German Society for Gastroenterology, Digestive and Metabolic Diseases tell doctors what they should pay attention to in screening, diagnosis and therapy. Brand new recommendations on hepatitis B virus infections are now included due to TherVacB scientists Prof. Markus Cornberg (Hannover Medical School, Germany) and Prof. Ulrike Protzer (Helmholtz Zentrum Munich, Germany) and other experts.
- In its ninth year, European Testing Week continues to encourage partner organisations in community, health care and policy in Europe to join forces this autumn to increase integrated testing efforts & promote awareness on the benefits of hepatitis and HIV testing.
- European Testing Week supports testing activities throughout the year: To find out where you can have a test for HIV, hepatitis or other sexually transmitted infections use the European Test Finder. Hundreds of testing services for viral hepatitis, HIV and STIs are registered.
- Find out more about the campaign on their website here.
An online discussion for the HBV community on scientific progress in Europe towards a cure features the European HBV Patient Registry.
The International Coalition for the Elimination of HBV, ICE-HBV, in partnership with Liver Patients International open the floor to an online discussion of updates on HBV Cure Research in Europe.
On Wednesday, 24th November 2021, 13:00 – 14:30 CET, leading scientists, researchers and clinicians will be discussing latest HBV cure-related research and scientific topics with patients, people living with HBV and the HBV community.
As part of the „B_Aware” awareness campaign about hepatitis B prevention, infection, therapy and cure research, TherVacB team member Prof. Dr. Markus Cornberg, Medical School Hannover, Germany, will introduce the newly established European HBV Patient Registry for patients living with chronic hepatitis.
Comments and questions from the audience will help to better engage people living with HBV in the research.
Haben Sie Fragen zur Virushepatitis?
Sprechen Sie im Rahmen einer speziellen Telefonsprechstunde zur Hepatitis B direkt mit Prof. Dr. Markus Cornberg, Erstautor der aktuellen Leitlinie zur Hepatitis B und Oberarzt an der Medizinischen Hochschule Hannover, einem der “TherVacB”-Prüfzentren.
Prof. Cornberg wird alle Fragen zur Hepatitis B beantworten – von „Was sind mögliche Wege der Ansteckung?“ oder “Trägt die gesetzliche Krankenkasse in Deutschland ein Screening auf Hepatitis B?” bis hin zu „Was bedeuten meine Leberwerte?“ und „Wie muss die Erkrankung behandelt werden?“.
Die Telefonsprechstunde zur Hepatitis B ist Teil der „B_Aware-Kampagne“ zur Aufklärung über Hepatitis B und findet anlässlich des Deutschen Lebertages am 16. November 2021 zwischen 16:00 und 18:00 Uhr statt. Sie erreichen Herrn Prof. Cornberg unter 01805 – 45 00 60. Für ein Telefonat fallen Verbindungskosten in Höhe von € 0,14/Min. aus dem deutschen Festnetz und max. € 0,42/Min. aus dem Mobilfunk an.
Weitere Informationen zur Lebergesundheit anlässlich des 22. Deutschen Lebertages finden Sie bei unserem Kooperationspartner, der Deutschen Leberstifung.
Every 30 seconds one person is dying from a hepatitis related illness. During the COVID-19 pandemic, there is a growing need to accelerate hepatitis elimination efforts. The TherVacB project team in Europe and Tanzania, working of clinical trial preparation on viral hepatitis B, remains fully dedicated to achieving the global elimination goal by 2030.
In times of COVID-19, European Testing Week aims to increase integrated testing efforts & promote awareness on the benefits of hepatitis and HIV testing!
This Spring European Testing Week 2021 and with COVID-19, we won’t be going back to “testing as usual”. Find out here about innovative testing strategies for viral hepatitis in times of COVID-19.
Now in its ninth year, the European campaign encourages partner organisations — in community, health care and policy institutions — throughout Europe to unite for one week in spring and in autumn to increase testing efforts and promote awareness on the benefits of earlier hepatitis and HIV testing.
Actually, European Testing Week supports testing activities throughout the year: To find out where you can have a test for HIV, hepatitis or other sexually transmitted infections use the European Test Finder. Hundreds of testing services for viral hepatitis, HIV and STIs are registered.
Find out more here.
Translations of the revised TherVacB website are now available in four languages!
To make info about the TherVacB vaccination study and the European HBV Registry more accessible to a Europen audience, we have partnered with researchers at study centres to produce this series of translations. The English version has now been joined by:
In addition to the TherVacB clinical trial, the TherVacB team has established a European registry for patients with chronic Hepatitis B. The European HBV Registry is currently active in Italy, Spain, UK and Germany and collects patient data on virological and immunological parameters during a hepatitis B virus infection. Every participant supports, with the data generated from him- or herself, to a better understanding of the HBV-mediated disease and to develop or refine therapies. Ultimately, this will help the community of patients in general!